Health care stocks were mixed pre-bell Friday as the iShares Biotechnology ETF (IBB) was 0.1% higher and the Health Care Select Sector SPDR Fund (XLV) was down 0.2% recently.
UnitedHealth Group (UNH) and Amedisys (AMED) extended the deadline for closing their $3.3 billion merger agreement as the US Department of Justice scrutinizes the deal, a filing showed. Amedisys shares rose past 4% premarket.
Takeda Pharmaceutical (TAK) shares were up over 1% after the company said the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.
Exicure (XCUR) shares advanced by about 9% after the company said it signed a memorandum of understanding with GPCR Therapeutics for the acquisition of the South Korean company's US subsidiary, GPCR USA, to advance its growth as a clinical-stage biotech firm.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。